# An Analysis of CMS Part D Spending 2015 - 2019

## Background/Description

This is an in-depth analysis of CMS Part D spending from 2015 through 2019 (link here), focused around products, brands and molecules that comprise the bulk of CMS Part D spend during these years, and how Part D spending has evolved over time.

![](CMS_screenshot.png)

## Key Findings

* Overall Part D spending **increased 37%**  from 2015 to 2019, up to $183B.
* The top brand by total Part D spend in 2019 was Eliquis, a blood thinner manufactured by Bristol-Myers Squibb.  The top brand by spend in 2015 was Gilead's Harvoni.
* The top manufacturer by spend in 2019 was Novo Nordisk with almost $10B in total spend.

![](top_drugs_by_spend.png)



